Literature DB >> 23346762

Pharmacokinetics of paeoniflorin microemulsion after repeated dosing in rats with adjuvant arthritis.

Chun Wang1, Jun Yuan, Zhao-Yi Yang, Xin-Xin Nie, Li-Hua Song, Wei Wei.   

Abstract

An investigation was designed and conducted to detect pharmacokinetic differences between paeoniflorin (Pae) microemulsion and Pae saline. Pae microemulsion (25, 50,100 mg x kg(-1)) was administered to three groups of rats with adjuvant arthritis (AA) while Pae (25, 50,100 mg x kg(-1)) was given to another three groups of rats both for ten days. A HPLC assay was developed to determine the plasma concentrations of Pae. The plasma concentrations of Pae groups (25, 50 mg x kg(-1)) were undetectable. Furthermore, compared with pharmacokinetic parameters of Pae group (100 mg x kg(-1)), maximum concentration (C(max)), the area under the plasma concentration-time curve (AUC(0-t)), and mean retention time MRT(0-infinity))(h) of Pae microemulsion (100 mg x kg(-1)) increased apparently, while volume of distribution (Vd) and clearance rate (CL/F) decreased. These results indicate that a microemulsion significantly improves the absorption of Pae in AA rats.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23346762

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  5 in total

1.  Paeoniflorin inhibits Th1 and Th17 cells in gut-associated lymphoid tissues to produce anti-arthritis activities.

Authors:  Fei Fei; Li-Xiang Aa; Qi Qi; Run-Bin Sun; Cai-Xia Yan; Ji-Ye Aa; Guang-Ji Wang
Journal:  Inflammopharmacology       Date:  2019-07-15       Impact factor: 4.473

2.  Effect of 6'-acetylpaeoniflorin on dinitrochlorobenzene-induced allergic contact dermatitis in BALB/c mice.

Authors:  Peng Zhou; Xiaodan Yang; Xiaoyi Jia; Jun Yu; James Asenso; Feng Xiao; Chun Wang; Wei Wei
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

3.  The tissue distribution and excretion study of paeoniflorin-6'-O-benzene sulfonate (CP-25) in rats.

Authors:  Mingyi Zhao; Peng Zhou; Jun Yu; Asenso James; Feng Xiao; Chun Wang; Wei Wei
Journal:  Inflammopharmacology       Date:  2018-03-09       Impact factor: 5.093

4.  CP-25, a novel compound, protects against autoimmune arthritis by modulating immune mediators of inflammation and bone damage.

Authors:  Yan Chang; Xiaoyi Jia; Fang Wei; Chun Wang; Xiaojing Sun; Shu Xu; Xuezhi Yang; Yingjie Zhao; Jingyu Chen; Huaxun Wu; Lingling Zhang; Wei Wei
Journal:  Sci Rep       Date:  2016-05-17       Impact factor: 4.379

5.  CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells.

Authors:  Min Zhang; Mei Gao; Jinyu Chen; Lihua Song; Wei Wei
Journal:  Mol Med Rep       Date:  2019-10-23       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.